Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. TMUS
5. PEP
6. AXP
7. T
8. SPY
9. CVS
10. UNH

Go back to Sarepta Therapeutics to Ring Nasdaq Stock Market Closing Bell in Recognition of World Duchenne Awareness Day

Sarepta (SRPT) SRP-4053 Data Provides 'Strong Validation' - SunTrust

September 6, 2017 11:54 AM EDT

SunTrust Robinson Humphrey analyst Edward Nash reiterated a Buy rating and $56 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive muscle biopsy results from the Phase I/II 4053-101 study that evaluated golodirsen (SRP-4053) for the treatment of DMD patients... More

Sarepta (SRPT) Could See Exon 53 Approval in 2018, Peak Sales of ~$800M - William Blair

September 6, 2017 11:06 AM EDT

William Blair analyst Tim Lugo weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive interim 48-week data from its ongoing European Phase I/II study for DMD patients amenable to skipping exon 53 with golodirsen (SRP-4053).

Lugo notes all... More

UPDATE: Sarepta Therapeutics (SRPT) PT Raised to $55 at Piper Jaffray

September 6, 2017 10:57 AM EDT

(Updated - September 6, 2017 11:00 AM EDT)

(updated to add analyst comment)

Piper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $55.00 (from $50.00) while maintaining a Overweight rating.

Analyst Edward Tenthoff notes the positive Exon 53 data. The analyst further comments... More